Science |Prilenia and Ferrer
Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease
October 22, 2026 · 4:34 AM · NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain
Prilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (clinicaltrialsregister.eu 2026-526093-16-00, clinicaltrials.gov NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, wi...
- PublishedOctober 22, 2026 · 4:34 AM
- LocationNAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →